PubTransformer

A site to transform Pubmed publications into these bibliographic reference formats: ADS, BibTeX, EndNote, ISI used by the Web of Knowledge, RIS, MEDLINE, Microsoft's Word 2007 XML.

A Potential of sFasL in Preventing Gland Injury in Sjogren's Syndrome.

Abstract Fas and its ligand FasL, members of tumor necrosis factor receptor superfamily, have been implicated in the process of cell apoptosis. FasL consists of two forms, membrane FasL (mFasL) and soluble FasL (sFasL). sFasL can be produced by mFasL cleaved by matrix metalloproteinases (MMP) and also reveals a role for binding to Fas which is expressed on cell surface. Although Fas/FasL axis has been implicated in a variety of diseases, its role in Sjogren's syndrome still remains ill defined. In this study, we investigated the potential of sFasL in the pathogenesis of Sjogren's syndrome (SS). We found that the serum levels of sFasL in SS patients were significantly lower than healthy subjects. Moreover, serum levels of sFasL in patients with mild disease activity were higher than patients with severe disease activity. There is a positive correlation of the serum level of sFasL with uptake index of parotid gland in our expectation. In addition, liver injury involvement in SS patients showed decreased level of sFasL. Furthermore, we here also observed that the protective cytokine IL-10 expression was positively correlated with sFasL expression. Thus, our results here suggest a potential of sFasL in maintaining gland organ homeostasis.
PMID
Related Publications

Matrix metalloproteinases and soluble Fas/FasL system as novel regulators of apoptosis in children and young adults on chronic dialysis.

Stromelysin-1 (MMP-3) in synovial fluid of patients with rheumatoid arthritis has potential to cleave membrane bound Fas ligand.

Fas ligand exerts its pro-inflammatory effects via neutrophil recruitment but not activation.

Distinct effects of soluble and membrane-bound fas ligand on fibroblast-like synoviocytes from rheumatoid arthritis patients.

Control of ocular tumor growth and metastatic spread by soluble and membrane Fas ligand.

Authors

Mayor MeshTerms
Keywords
Journal Title biomed research international
Publication Year Start




PMID- 28326325
OWN - NLM
STAT- In-Process
DA  - 20170322
LR  - 20170322
IS  - 2314-6141 (Electronic)
VI  - 2017
DP  - 2017
TI  - A Potential of sFasL in Preventing Gland Injury in Sjogren's Syndrome.
PG  - 5981432
LID - 10.1155/2017/5981432 [doi]
AB  - Fas and its ligand FasL, members of tumor necrosis factor receptor superfamily,
      have been implicated in the process of cell apoptosis. FasL consists of two
      forms, membrane FasL (mFasL) and soluble FasL (sFasL). sFasL can be produced by
      mFasL cleaved by matrix metalloproteinases (MMP) and also reveals a role for
      binding to Fas which is expressed on cell surface. Although Fas/FasL axis has
      been implicated in a variety of diseases, its role in Sjogren's syndrome still
      remains ill defined. In this study, we investigated the potential of sFasL in the
      pathogenesis of Sjogren's syndrome (SS). We found that the serum levels of sFasL 
      in SS patients were significantly lower than healthy subjects. Moreover, serum
      levels of sFasL in patients with mild disease activity were higher than patients 
      with severe disease activity. There is a positive correlation of the serum level 
      of sFasL with uptake index of parotid gland in our expectation. In addition,
      liver injury involvement in SS patients showed decreased level of sFasL.
      Furthermore, we here also observed that the protective cytokine IL-10 expression 
      was positively correlated with sFasL expression. Thus, our results here suggest a
      potential of sFasL in maintaining gland organ homeostasis.
FAU - Luo, Jiao
AU  - Luo J
AUID- ORCID: 0000-0001-8649-7916
AD  - Department of Rheumatology and Clinical Immunology, The First Hospital of Xiamen 
      University, Xiamen 361003, China; Xiamen Key Laboratory of Rheumatology and
      Clinical Immunology, Xiamen, China.
FAU - Wang, Ying
AU  - Wang Y
AD  - The Chenggong Hospital Affiliated to Xiamen University, Xiamen, Fujian, China.
FAU - Yu, Bing
AU  - Yu B
AD  - Department of Rheumatology and Clinical Immunology, The First Hospital of Xiamen 
      University, Xiamen 361003, China; Xiamen Key Laboratory of Rheumatology and
      Clinical Immunology, Xiamen, China.
FAU - Qian, Hongyan
AU  - Qian H
AUID- ORCID: 0000-0003-0076-8194
AD  - Department of Rheumatology and Clinical Immunology, The First Hospital of Xiamen 
      University, Xiamen 361003, China; Xiamen Key Laboratory of Rheumatology and
      Clinical Immunology, Xiamen, China.
FAU - He, Yan
AU  - He Y
AUID- ORCID: 0000-0002-4316-8298
AD  - Department of Rheumatology and Clinical Immunology, The First Hospital of Xiamen 
      University, Xiamen 361003, China; Xiamen Key Laboratory of Rheumatology and
      Clinical Immunology, Xiamen, China.
FAU - Shi, Guixiu
AU  - Shi G
AUID- ORCID: 0000-0003-4044-3394
AD  - Department of Rheumatology and Clinical Immunology, The First Hospital of Xiamen 
      University, Xiamen 361003, China; Xiamen Key Laboratory of Rheumatology and
      Clinical Immunology, Xiamen, China.
LA  - eng
PT  - Journal Article
DEP - 20170223
PL  - United States
TA  - Biomed Res Int
JT  - BioMed research international
JID - 101600173
PMC - PMC5343225
COI - The authors declare no conflict of interests regarding the publication of this
      paper.
EDAT- 2017/03/23 06:00
MHDA- 2017/03/23 06:00
CRDT- 2017/03/23 06:00
PHST- 2016/10/26 [received]
PHST- 2017/02/06 [accepted]
AID - 10.1155/2017/5981432 [doi]
PST - ppublish
SO  - Biomed Res Int. 2017;2017:5981432. doi: 10.1155/2017/5981432. Epub 2017 Feb 23.

<?xml version="1.0" encoding="UTF-8"?>
<b:Sources SelectedStyle="" xmlns:b="http://schemas.openxmlformats.org/officeDocument/2006/bibliography"  xmlns="http://schemas.openxmlformats.org/officeDocument/2006/bibliography" >
</b:Sources>